Evidence map›Paper›PMID 33257451›Full record

ArticleAntimicrobial agents and chemotherapy2021

A Matched Case-Case-Control Study of the Impact of Clinical Outcomes and Risk Factors of Patients with IMP-Type Carbapenemase-Producing Carbapenem-Resistant

Sho Saito, Kayoko Hayakawa, Shinya Tsuzuki, Masahiro Ishikane, Maki Nagashima, Kazuhisa Mezaki, Yuko Sugiki, Taichi Tajima, Nobuaki Matsunaga, Satoshi Ide and 8 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 2 countries.

Sho SaitoDisease Control and Prevention Center, National Centre for Global Health and Medicine, Tokyo, Japan sho-87@hotmail.co.jp.ORCID 0000-0002-9981-7584
Kayoko HayakawaDisease Control and Prevention Center, National Centre for Global Health and Medicine, Tokyo, Japan.
Shinya TsuzukiAMR Clinical Reference Center, National Centre for Global Health and Medicine, Tokyo, Japan.
Masahiro IshikaneDisease Control and Prevention Center, National Centre for Global Health and Medicine, Tokyo, Japan.
Maki NagashimaDisease Control and Prevention Center, National Centre for Global Health and Medicine, Tokyo, Japan.
Kazuhisa MezakiMicrobiology Laboratory, National Center for Global Health and Medicine, Tokyo, Japan.
Yuko SugikiInfection Control and Prevention, National Center for Global Health and Medicine, Tokyo, Japan.
Taichi TajimaAMR Clinical Reference Center, National Centre for Global Health and Medicine, Tokyo, Japan.
Nobuaki MatsunagaAMR Clinical Reference Center, National Centre for Global Health and Medicine, Tokyo, Japan.
Satoshi IdeDisease Control and Prevention Center, National Centre for Global Health and Medicine, Tokyo, Japan.
Noriko KinoshitaDisease Control and Prevention Center, National Centre for Global Health and Medicine, Tokyo, Japan.
Yoshiki KusamaAMR Clinical Reference Center, National Centre for Global Health and Medicine, Tokyo, Japan.
Yumiko FujitomoAMR Clinical Reference Center, National Centre for Global Health and Medicine, Tokyo, Japan.
Takato NakamotoDisease Control and Prevention Center, National Centre for Global Health and Medicine, Tokyo, Japan.
Yuta TodaDisease Control and Prevention Center, National Centre for Global Health and Medicine, Tokyo, Japan.
Mitsuo KakuDepartment of Infection Control and Laboratory Diagnostics, Tohoku University School of Medicine, Sendai, Miyagi, Japan.
Eiichi N KodamaDivision of Infectious Diseases, School of Medicine, International Research Institute of Disaster Science, and Tohoku Medical Megabank Organization, Tohoku University, Sendai, Miyagi, Japan.
Norio OhmagariDisease Control and Prevention Center, National Centre for Global Health and Medicine, Tokyo, Japan.
National Center for Global Health and Medicine · JPTohoku University · JPUniversity of Antwerp · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IMP-type carbapenemase, found in various Gram-negative bacteria, has been increasingly detected worldwide. We aimed to study the outcomes and risk factors for acquisition of IMP-type carbapenemase-producing carbapenem-resistant

Indexed as

Carbapenem-Resistant EnterobacteriaceaeEnterobacteriaceae InfectionsAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCarbapenemsCase-Control StudiesHumansJapanRisk FactorsAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasescarbapenemaseCarbapenemscarbapenem resistanceclinical outcomesEnterobacteriaceaeIMPpropensity score

Identifiers

PMID33257451
PMCPMC8092526
OpenAlexW3110269431

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.